Viridian Therapeutics, Inc./DE (VRDN) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
36/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseVRDN / S&P -6.08% / 15.20% |
WinVRDN / S&P 23220.33% / 15.00% |
LoseVRDN / S&P VRDN unavailable / 50.40% |
| 2026-Q11/3 |
LoseVRDN / S&P -37.15% / -4.33% |
WinVRDN / S&P 23382.78% / 11.30% |
LoseVRDN / S&P VRDN unavailable / 27.70% |
| 2025-Q42/3 |
WinVRDN / S&P 44.21% / 2.65% |
WinVRDN / S&P 23359.93% / 9.00% |
LoseVRDN / S&P VRDN unavailable / 13.40% |
| 2025-Q32/3 |
WinVRDN / S&P 54.36% / 8.12% |
WinVRDN / S&P 23340.07% / 4.61% |
LoseVRDN / S&P VRDN unavailable / 13.45% |
| 2025-Q21/3 |
LoseVRDN / S&P 3.71% / 10.94% |
WinVRDN / S&P 5.90% / 4.83% |
LoseVRDN / S&P VRDN unavailable / 10.63% |
| 2025-Q10/3 |
LoseVRDN / S&P -29.68% / -4.27% |
LoseVRDN / S&P 4.86% / 4.98% |
LoseVRDN / S&P VRDN unavailable / 10.57% |
| 2024-Q40/3 |
LoseVRDN / S&P -15.74% / 2.41% |
LoseVRDN / S&P -3.82% / 5.25% |
LoseVRDN / S&P VRDN unavailable / 6.15% |
| 2024-Q31/3 |
WinVRDN / S&P 74.87% / 5.89% |
LoseVRDN / S&P -12.97% / 5.89% |
LoseVRDN / S&P -16.34% / 6.11% |
| 2024-Q20/3 |
LoseVRDN / S&P -25.70% / 4.28% |
LoseVRDN / S&P -80.41% / 5.38% |
LoseVRDN / S&P -13.65% / 5.12% |
| 2024-Q10/3 |
LoseVRDN / S&P -19.61% / 10.56% |
LoseVRDN / S&P -82.59% / 5.71% |
LoseVRDN / S&P -4.47% / 5.59% |
| 2023-Q42/3 |
WinVRDN / S&P 41.98% / 11.69% |
LoseVRDN / S&P -82.28% / 6.81% |
WinVRDN / S&P 30.47% / 7.78% |
| 2023-Q31/3 |
LoseVRDN / S&P -35.52% / -3.27% |
LoseVRDN / S&P -81.55% / 7.52% |
WinVRDN / S&P 42.38% / -5.03% |
| 2023-Q22/3 |
LoseVRDN / S&P -6.49% / 8.74% |
WinVRDN / S&P 64.43% / 9.50% |
WinVRDN / S&P 22.75% / -8.57% |
| 2023-Q11/3 |
LoseVRDN / S&P -12.91% / 7.50% |
LoseVRDN / S&P -4.28% / 10.77% |
WinVRDN / S&P -8.74% / -15.69% |
| 2022-Q41/3 |
WinVRDN / S&P 42.42% / 7.56% |
LoseVRDN / S&P -40.20% / 11.88% |
LoseVRDN / S&P -42.51% / -17.99% |
| 2022-Q31/3 |
WinVRDN / S&P 77.27% / -4.88% |
LoseVRDN / S&P -32.89% / 13.47% |
LoseVRDN / S&P -88.60% / -1.41% |
| 2022-Q20/3 |
LoseVRDN / S&P -37.43% / -16.10% |
LoseVRDN / S&P -65.55% / 13.71% |
LoseVRDN / S&P -87.46% / 11.04% |
| 2022-Q10/3 |
LoseVRDN / S&P -6.47% / -4.60% |
LoseVRDN / S&P 3.29% / 15.97% |
LoseVRDN / S&P -83.66% / 42.23% |
| 2021-Q42/3 |
WinVRDN / S&P 20.18% / 11.03% |
WinVRDN / S&P 182.19% / 15.00% |
LoseVRDN / S&P VRDN unavailable / 96.40% |
| 2021-Q31/3 |
LoseVRDN / S&P -10.06% / 0.58% |
WinVRDN / S&P 49.41% / 10.77% |
LoseVRDN / S&P VRDN unavailable / 69.42% |
| 2021-Q21/3 |
WinVRDN / S&P 9.46% / 8.55% |
LoseVRDN / S&P 0.93% / 6.58% |
LoseVRDN / S&P VRDN unavailable / 51.81% |
| 2021-Q10/3 |
LoseVRDN / S&P 1.58% / 6.17% |
LoseVRDN / S&P -65.98% / -1.06% |
LoseVRDN / S&P VRDN unavailable / 7.39% |
| 2020-Q41/3 |
WinVRDN / S&P 41.51% / 12.15% |
LoseVRDN / S&P -76.46% / -3.72% |
LoseVRDN / S&P VRDN unavailable / -33.42% |
| 2020-Q30/3 |
LoseVRDN / S&P -30.18% / 8.93% |
LoseVRDN / S&P -53.76% / -2.04% |
LoseVRDN / S&P VRDN unavailable / -27.10% |
| 2020-Q21/3 |
WinVRDN / S&P 148.88% / 20.54% |
LoseVRDN / S&P -40.29% / -0.46% |
LoseVRDN / S&P VRDN unavailable / -27.11% |
| 2020-Q12/3 |
WinVRDN / S&P -7.08% / -19.60% |
WinVRDN / S&P 23.73% / 3.47% |
LoseVRDN / S&P VRDN unavailable / -14.75% |
| 2019-Q40/3 |
LoseVRDN / S&P -34.34% / 9.07% |
LoseVRDN / S&P -46.80% / 5.36% |
LoseVRDN / S&P VRDN unavailable / 2.99% |
| 2019-Q30/3 |
LoseVRDN / S&P -64.34% / 1.70% |
LoseVRDN / S&P -55.43% / 5.02% |
LoseVRDN / S&P VRDN unavailable / 0.21% |
| 2019-Q20/3 |
LoseVRDN / S&P -26.52% / 4.30% |
LoseVRDN / S&P -56.01% / 6.64% |
LoseVRDN / S&P VRDN unavailable / 8.65% |
| 2019-Q10/3 |
LoseVRDN / S&P -7.92% / 13.65% |
LoseVRDN / S&P -52.26% / 8.12% |
LoseVRDN / S&P VRDN unavailable / 14.29% |
| 2018-Q41/3 |
LoseVRDN / S&P -45.70% / -13.52% |
WinVRDN / S&P 109.49% / 9.05% |
LoseVRDN / S&P VRDN unavailable / 18.23% |
| 2018-Q31/3 |
LoseVRDN / S&P -12.95% / 7.71% |
WinVRDN / S&P 174.16% / 10.21% |
LoseVRDN / S&P VRDN unavailable / 19.06% |
| 2018-Q21/3 |
LoseVRDN / S&P -8.56% / 3.43% |
WinVRDN / S&P 272.91% / 9.03% |
LoseVRDN / S&P VRDN unavailable / 14.46% |
| 2018-Q11/3 |
LoseVRDN / S&P -32.79% / -0.76% |
WinVRDN / S&P 175.48% / 7.68% |
LoseVRDN / S&P VRDN unavailable / 12.46% |
| 2017-Q42/3 |
WinVRDN / S&P 13.99% / 6.64% |
WinVRDN / S&P 15.13% / 7.03% |
LoseVRDN / S&P VRDN unavailable / 13.82% |
| 2017-Q30/3 |
LoseVRDN / S&P -29.23% / 4.48% |
LoseVRDN / S&P -8.46% / 5.68% |
LoseVRDN / S&P VRDN unavailable / 17.57% |
| 2017-Q21/3 |
WinVRDN / S&P 3.94% / 3.09% |
LoseVRDN / S&P -17.76% / 4.83% |
LoseVRDN / S&P VRDN unavailable / 17.74% |
| 2017-Q12/3 |
WinVRDN / S&P 148.30% / 6.07% |
WinVRDN / S&P 7.51% / 3.67% |
LoseVRDN / S&P VRDN unavailable / 13.32% |
| 2016-Q41/3 |
LoseVRDN / S&P -33.20% / 3.82% |
WinVRDN / S&P 36.94% / 2.09% |
LoseVRDN / S&P VRDN unavailable / 7.05% |
| 2016-Q32/3 |
WinVRDN / S&P 17.65% / 3.85% |
WinVRDN / S&P 43.08% / 0.20% |
LoseVRDN / S&P VRDN unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | VRDN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 29.92% | 20.78% |
| Annualized return | 29.92% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | VRDN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 81.32% | 83.14% |
| Annualized return | 12.64% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | VRDN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -77.98% | 319.30% |
| Annualized return | -14.04% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |